Kabra Drugs Ltd

Healthcare · Pharmaceuticals & Biotechnology

BSE: 524322
₹19.49
Sept. 30, 2026 · BSE · bse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #154 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

CompanyMarket cap (₹ Cr)PE (TTM)ROE1Y returnDiv. yieldQualityValuationMomentum
Sun Pharmaceutical Industries Limited 435,863 146.5 13.7% 11.0% — 72 8 30
Divi's Laboratories Limited 246,660 83.9 15.3% 62.7% 0.32% 70 4 51
Torrent Pharmaceuticals Limited 162,454 78.2 12.2% 34.6% 0.79% 56 0 31
Zydus Lifesciences Limited 115,910 33.3 17.3% 17.2% 0.09% 74 24 84
Cipla Limited 108,736 35.4 11.2% -11.0% 0.97% 73 29 62
Laurus Labs Limited 106,969 122.5 17.1% 127.1% — 78 24 53
Mankind Pharma Limited 103,406 47.4 11.7% 2.6% — 68 12 86
Dr. Reddy's Laboratories Limited 102,916 154.7 10.9% -0.9% — 62 33 71
Kabra Drugs Ltd (this stock) 46 6.1 1.4% 146.4% — 61 96 50

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value
₹36 Cr
EV / EBITDA
3.9x
EV / Sales
0.27x
Market cap / Sales
0.35x
Earnings yield
16.42%

Quarterly Financials

↑ Positive
Quarterly Revenue

Jun 2026 quarterly revenue is Rs 46 Cr, up 546.0% YoY.

↓ Negative
Quarterly Net Profit

Jun 2026 quarterly net profit is Rs 2 Cr, down 524.6% YoY.

Period endRevenue (₹ Cr)PBT (₹ Cr)Net profit (₹ Cr)Basic EPS
June 30, 2026 46 3 2 ₹0.9000
March 31, 2026 35 1 — ₹0.4500
Dec. 31, 2025 30 3 — ₹1.0800
Sept. 30, 2025 20 2 2 ₹0.7700
June 30, 2025 7 -0 -0 ₹-0.2100
March 31, 2025 1 0 — ₹0.2100
Dec. 31, 2024 — -1 -1 ₹-0.5300
Sept. 30, 2024 — -0 -0 ₹-3.9400
June 30, 2024 — -1 -1 ₹-1.2400
March 31, 2024 — -0 -0 ₹-0.8400
Dec. 31, 2023 — -0 -0 ₹-0.2500
Sept. 30, 2023 — -0 -0 ₹-0.3100
June 30, 2023 — -0 -0 ₹-0.2800

Quarterly income statement (standalone, ₹ Cr)

IndicatorJun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23
Total income (before exceptional items)4636312071———————
Operating revenue4635302070———————
Other income000001———————
Operating expenses4334281880———————
Operating profit3122-1-0———————
Operating profit margin6.0%3.8%8.0%10.3%-7.2%————————
Depreciation00000000—————
Interest000000———————
Exceptional items, gain / (loss)—————————————
Profit before tax3132-00-1-0-1-0-0-0-0
Tax1000—-000—————
Net profit2——2-0—-1-0-1-0-0-0-0
EPS0.900.451.080.77-0.210.21-0.53-3.94-1.24-0.84-0.25-0.31-0.28
Net profit (TTM)——————-2-1-1-1-1-0-0
EPS (TTM)3.202.091.850.24-4.47-5.50-6.55-6.27-2.64-1.68-1.16-1.05-0.88

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

IndicatorCAGR 3YCAGR 5YMar 26Mar 25Mar 24Mar 23Mar 22Mar 21Mar 20Mar 18Mar 17
Total income (before exceptional items) — — 93†————————
Operating revenue — — 93†———————8†
Other income — — 0†————————
Operating expenses — — 87†————————
Operating profit — — 5†————————
Operating profit margin — — 5.7%†————————
Depreciation — — 0†——————0†0†
Interest — — 0†————————
Exceptional items, gain / (loss) — — 0†0†0†0†0†0†0†-1†0†
Profit before tax — — 6†-1†-1†-0†-0†-0†-0†-2†0†
Tax — — —————————
Net profit — — ——-1†-0†-0†-0†-0†-2†-0†
EPS — — 2.09†-5.50†-1.68†-0.77†-0.42†————

† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

RatioMar 26Mar 25Mar 24Mar 23Mar 22Mar 21Mar 20Mar 18Mar 17
Operating margin5.7%†————————
EBIT margin6.2%†————————
PBT margin6.2%†———————0.0%†
Net margin————————-0.1%†
Interest coverage333.91x†————————
Dividend payout—————————
Earnings retention—————————
Current ratio1.49x43.84x———————
Quick ratio1.49x43.84x———————
Debt to equity0.01x0.02x———————
Return on equity—————————
Return on assets—————————
Return on capital employed19.3%†————————
Asset turnover1.07x†————————

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year endedOperating (₹ Cr)Investing (₹ Cr)Financing (₹ Cr)Capex (₹ Cr)Free Cash Flow (₹ Cr)
March 31, 2026 -9 -1 0 1 -10
March 31, 2025 -5 -0 23 0 -5

Balance Sheet (standalone)

Year endedTotal Assets (₹ Cr)Total Equity (₹ Cr)Reserves (₹ Cr)Borrowings, Current (₹ Cr)Borrowings, Non-current (₹ Cr)Current Assets (₹ Cr)Current Liabilities (₹ Cr)Cash & Equivalents (₹ Cr)Net Block (₹ Cr)Inventory (₹ Cr)
March 31, 2026 86 30 6 0 0 84 57 11 1 0
March 31, 2025 25 25 1 0 0 25 1 21 0 0

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.